Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Early results presented for dual CAR-T therapy

Liu F et al. EHA Congress, Abstract S149.

Publish date:: June 27, 2018

Key clinical point: The compound CAR T therapy targets CLL1 on leukemic stem cells and CD33 on bulky disease.

Major finding: The only human patient treated with the construct had a complete remission and successful bridge to transplant.

Study details: Preclinical study plus phase 1 data on one patient.

Disclosures: The study was supported by iCell Gene Therapeutics. Dr. Liu reported having no conflicts of interest.

Read the article.

Citation:

Liu F et al. EHA Congress, Abstract S149.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in CLL

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

Pigment traits, sun sensitivity associated with risk of non-Hodgkin lymphomas and chronic lymphocytic leukemia,

Ibrutinib associated with decreased circulating malignant cells and restored T-cell function in CLL patients,

Final ASCEND study data: Acalabrutinib beat standard of care for r/r CLL,

Meta-analysis: Acalabrutinib showed better PFS and OS than other frontline CLL therapies,

All Specialties